CD274 and small cell lung carcinoma: The present study may provide a rationale to conduct clinical studies of anti-PD-L1 antibodies in combination with topoisomerase I inhibitors, irinotecan, in small cell lung cancer, gastrointestinal cancer, and breast cancer.